Subjects of group 2 did not show any significant protection against EAR after placebo + BDP treatment ( T3 ) MaxdeltaFEV1 % at T2 ( median , 31 % ; range , 9 to 40 % ) and T3 ( median , 31 % ; range , 3 to 42 % ; not significant ) .
